-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Amgen, Raises Price Target to $542

Benzinga·11/19/2026 15:12:55
Listen to the news
Piper Sandler analyst David Amsellem reiterates Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $457 to $542.